SCI outsourcing expected to aid sales after factory fireBy Chen Cheng-hui / Staff reporterSCI Pharmtech Inc’s (SCI, 旭富製藥) plans to outsource production of intermediates to other Taiwanese firms are expected to help recover some of its lost sales, after its plant in Taoyuan’s Lujhu District (蘆竹) was severely damaged by a fire on Sunday last week, analysts said this week. Firefighters and security guards stand outside SCI Pharmtech Inc’s plant in Taoyuan’s Lujhu District on Tuesday last week. Photo: Wei Chin-yun, Taipei TimesSCI produces active pharmaceutical ingredients (API), intermediates and specialty chemicals, with intermediates contributing 26.66 percent to its total sales in 2019. In a regulatory filing on Friday last week, SCI said it was discussing with local manufacturers about outsourcing some production during the rebuild of its lines. The company would likely post losses for last year, with estimated losses per share of NT$1.15, compared with earnings per share of NT$7.19 in 2019.

Source: Taipei Times December 31, 2020 15:56 UTC